why choose us

First received: November 20, 2023

Clinical Trial: SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Cystic Fibrosis-related Diabetes

Study Type: INTERVENTIONAL


Official Title: Empagliflozin in CFRD: Efficacy and Safety of SGLT2 Inhibitor Therapy in Overweight and Obese Subjects With Cystic Fibrosis-related Diabetes: a Pilot Study

Brief Summary: This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period.Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients with CFRD to support a future larger randomized controlled trial.

Read more